Jaguar Health Collaborates with Andelyn to Develop Gene Therapy JAG201 for Autism Disorder

Jaguar Health Partners with Andelyn Biosciences to Advance Gene Therapy for Autism Spectrum Disorder

In a significant collaboration, Andelyn Biosciences and Jaguar Gene Therapy join forces to propel the late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, a promising investigational gene therapy targeting SHANK3 haploinsufficiency. This genetic condition is a primary cause of Phelan-McDermid syndrome (PMS), a severe form of autism spectrum disorder characterized by profound neurobehavioral and cognitive challenges. Currently, effective medications to address the root causes of PMS are nonexistent, with existing treatments only capable of managing specific symptoms. The partnership aims to fill this critical gap in therapeutic options for individuals affected by this debilitating condition.

JAG201 utilizes an adeno-associated virus (AAV9) vector to deliver a functional SHANK3 minigene directly to neurons in the central nervous system, with the goal of restoring essential synaptic function. This approach is crucial for improving cognitive abilities and motor skills in patients diagnosed with PMS. Andelyn's expertise in AAV vector manufacturing and adherence to Good Manufacturing Practices (GMP) positions it as an ideal partner for Jaguar in the pursuit of bringing JAG201 closer to commercial availability. Both companies express a shared commitment to enhancing patient outcomes through innovative gene therapies, underlining the urgency of addressing the significant unmet medical needs of those suffering from SHANK3-related autism.

Matt Niloff, Chief Commercial Officer at Andelyn, articulates the mutual goal of the partnership: to enhance the quality of life for patients who currently have limited options. Meanwhile, Rob Mancino, Senior Vice President of Technical Operations at Jaguar, emphasizes the advantages of Andelyn's manufacturing experience during this critical phase of JAG201's development. This collaboration not only signifies a major step forward in gene therapy for autism but also highlights the potential for innovative solutions in addressing complex genetic disorders, paving the way for more effective treatments for conditions that have long been poorly managed.

Additionally, this partnership reflects a growing trend in the life sciences sector, where collaborations between biotech firms leverage specialized expertise to expedite the development of groundbreaking therapies. The advancements in gene therapy and manufacturing processes are crucial as the industry moves towards more personalized and effective treatment options. As both companies work diligently to transition JAG201 from the laboratory to the clinic, the focus remains on delivering hope and improved outcomes for patients and families grappling with the challenges posed by Phelan-McDermid syndrome.